Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group Identifier:
First received: May 6, 2001
Last updated: January 23, 2013
Last verified: January 2013